Smaller Drug Makers Actively Expanding Overseas Focus, Shedding Conventional Business Models

Both top-tier and smaller Japanese drug makers have been increasing their overseas business and operations. Mitsubishi Tanabe Pharma Corporation’s (MTPC) next midterm business plan (FY2016 through FY2020) will call for an increase in the company’s overseas sales ratio to 30%,...read more